Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06186752
Other study ID # 23-2704
Secondary ID R03TR004311-01A1
Status Recruiting
Phase N/A
First received
Last updated
Start date February 5, 2024
Est. completion date September 2025

Study information

Verified date December 2023
Source University of North Carolina, Chapel Hill
Contact Neal deJong, MD
Phone 919-966-2504
Email dejong@med.unc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this interventional study is to test the feasibility of a new communication tool, call MyIBD, in youth ages 13 to 19 years with inflammatory bowel disease. The main question[s] it aims to answer are: - Is the MyIBD communication tool feasible to use in everyday clinical practice? - Does the MyIBD tool have potential to improve patients' self-management skills and the quality of care they receive? Participants who receive the MyIBD intervention will complete surveys about their care at three times points - at study enrollment, at 6 months, and at 12 months. The surveys will help the research team learn about the feasibility of using MyIBD in practice and about any effects on patients' self-management skills and quality of care. Researchers will compare those receiving a MyIBD document to a randomly selected control group (patients receiving usual care for pediatric inflammatory bowel disease) to see if self-management skills and quality of care differ between the groups.


Description:

Quality of care for youth with chronic disease suffers because of gaps in care coordination and communication among patients/families and multiple health care providers. As youth with inflammatory bowel disease (IBD) have preventive and acute care needs beyond those of peers, IBD provides an excellent use case to evaluate interventions to enhance coordination and improve quality. Electronic health records (EHRs) have unfulfilled potential to facilitate coordination and effective action among teams of providers and families. This project leverages web-based and mobile phone application access points to share patient-specific information from an IBD center's EHR. The intervention, MyIBD, has been developed with systematic input from patients, families, and providers. Our objective is to assess the feasibility of delivering tailored guidance on IBD-related health needs to families and care team members using a low-cost, low-risk health communication innovation using existing health information technology. The rationale is that brief, actionable, individually tailored guidance from IBD specialists to families and other providers will support decisions about seeking and providing timely preventive and acute care. Though the intervention builds on prior work and evidence and has been pilot tested, it requires feasibility testing in practice prior to large-scale evaluation. We will assess feasibility of MyIBD through a pilot randomized, controlled trial at one site (n=60). The study has three research aims: (1) assess the feasibility of a rollout effectiveness trial design; (2) assess the feasibility and acceptability of implementing MyIBD in a pediatric IBD clinic; (3) explore the feasibility of MyIBD to improve (a) care quality measures collected from participants and the EHR and (b) patient self-management. In Aim 1 we will assess subject recruitment, randomization, retention, intervention completion, and contamination of control subjects using a study log. For Aim 2 we will use interviews (will take place after completion of the feasibility trial) and surveys to learn about barriers and facilitators of adoption by IBD clinics and acceptability and appropriateness from the perspectives of patients/families and care providers. For Aim 3 we will use surveys and medical record data to explore change over time in family-reported care quality, patient self-management, and completion of guideline-supported quality indicators for pediatric IBD for intervention and control groups. This project is innovative in seeking to change the default ways that care team members share information and address shared responsibilities. MyIBD targets well-described barriers to coordination and incorporates behavioral strategies of individual tailoring, family participation, expert modeling, and facilitation to streamline information delivery and enhance its relevance, accessibility, and actionability. The proposed study is significant because of its potential to improve health through a low-cost intervention to enhance use of existing health information technology. The study's findings could provide a framework for EHR-supported quality improvements through learning health system research across a range of childhood-onset chronic diseases.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 2025
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 13 Years to 19 Years
Eligibility Inclusion Criteria: - age 13-19 years old at time of recruitment; AND - diagnosis at least 3 months earlier of Crohn's disease, ulcerative colitis, or indeterminate colitis (to exclude families who have not had sufficient time to become familiar with condition and/or clinic personnel); AND - receiving ongoing care at UNC (at least one visit in the past year) Exclusion Criteria: - speaker of a language other than English or Spanish

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
MyIBD
MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.

Locations

Country Name City State
United States University of North Carolina-Chapel Hill School of Medicine Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill National Center for Advancing Translational Sciences (NCATS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of overall participants who completed a primary care health supervision visit in the past year, baseline Number (0-60) of participants who report having a primary care health supervision visit with a primary care provider in the past year Measured by self-report in baseline survey; reported at end of study year 1
Other Number of overall participants who completed a primary care health supervision visit in the past year, 12 months Number (0-60) of participants who report having a primary care health supervision visit with a primary care provider in the past year Measured by self-report in 12-month survey; reported at end of study year 2
Other Number of overall participants who completed special vaccine recommendations, baseline Number (0-unknown) of participants who report having completed all special vaccines recommended by IBD clinician (such as Hepatitis B booster dose, pneumococcal polysaccharide vaccine) Measured by self-report in baseline survey; reported at end of study year 1
Other Number of overall participants who completed special vaccine recommendations, 12 months Number (0-unknown) of participants who report having completed all special vaccines recommended by IBD clinician (such as Hepatitis B booster dose, pneumococcal polysaccharide vaccine) Measured by self-report in 12-month survey; reported at end of study year 2
Other Number of overall participants who participated in mood disorder screening in the past year, baseline Number (0-60) of participants who report participating in any mood disorder screening in the past year Measured by self-report in baseline survey; reported at end of study year 1
Other Number of overall participants who participated in mood disorder screening in the past year, 12 months Number (0-60) of participants who report participating in any mood disorder screening in the past year Measured by self-report in 12-month survey; reported at end of study year 2
Other Average number of non-injury-related visits to an emergency department (ED) in the past year, baseline Total count of non-injury-related ED visits by participants in the past year divided by the total number of participants Measured by self-report in baseline survey; reported at end of study year 1
Other Average number of non-injury-related visits to an emergency department (ED) in the past year, 12 months Total count of non-injury-related ED visits by participants in the past year divided by the total number of participants Measured by self-report in 12-month survey; reported at end of study year 2
Primary Number of overall participants recruited and randomized Number (0-60) will be an indicator of feasibility of implementing MyIBD in practice. Measured and reported at the end of study year 1
Primary Number of intervention group participants who receive a MyIBD document Number (0-30) of intervention-group participants who receive a MyIBD document will estimate the degree of completion of the intervention in practice. Measured and reported at the end of study year 1
Primary Number of overall participants retained through baseline survey Number (0-60) of participants who complete the baseline survey Measured and reported at the end of study year 1
Primary Number of overall participants retained through 6-month survey Number (0-60) of participants who complete the 6-month survey Measured and reported at the mid-point of study year 2
Primary Number of overall participants retained through 12-month survey Number (0-60) of participants who complete the 12-month survey Measured and reported at end of study year 2
Primary Number of control group participants who receive a MyIBD document Number (0-30) of control-group participants who (inappropriately) receive a MyIBD document is an indicator of contamination, or spreading the intervention in practice to the control group. Measured and reported at the end of study year 1
Primary Number of intervention group participants who agree or completely agree that MyIBD is an acceptable intervention using the Acceptability of Intervention Measure Measured in the 12-month participant survey using the Acceptability of Intervention Measure (AIM), a four-item scale with five Likert-type response options from 1=Completely disagree to 5=Completely agree. Item scores are averaged to yield a scale score, with 1 indicating the lowest level of acceptability and 5 indicating the highest level. Reported at the end of study year 2
Primary Number of intervention group participants who agree or completely agree that MyIBD is an appropriate intervention using the Intervention Appropriateness Measure Measured in the 12-month participant survey using the Intervention Appropriateness Measure (IAM), a four-item scale with five Likert-type response options from 1=Completely disagree to 5=Completely agree. Item scores are averaged to yield a scale score, with 1 indicating the lowest level of appropriateness and 5 indicating the highest level. Reported at the end of study year 2
Secondary Mean self-management score on the Partners in Health scale at baseline Measured in the baseline participant survey using the Partners in Health Scale, a 12-item survey with 9 Likert-type response options from 0=Very Little/Never to 8=A Lot/Always. Item scores are summed to yield a total scale score from 0, indicating the lowest level of self-management skill, to 96, indicating the highest level of self-management skill. Measured in each participant's baseline survey; reported at end of study year 1
Secondary Mean self-management score on the Partners in Health scale at 6 months Measured in the 6-month participant survey using the Partners in Health Scale, a 12-item survey with 9 Likert-type response options from 0=Very Little/Never to 8=A Lot/Always. Item scores are summed to yield a total scale score from 0, indicating the lowest level of self-management skill, to 96, indicating the highest level of self-management skill. Measured in each participant's 6-month survey; reported at end of study year 2
Secondary Mean self-management score on the Partners in Health scale at 12 months Measured in the 12-month participant survey using the Partners in Health Scale, a 12-item survey with 9 Likert-type response options from 0=Very Little/Never to 8=A Lot/Always. Item scores are summed to yield a total scale score from 0, indicating the lowest level of self-management skill, to 96, indicating the highest level of self-management skill. Measured in each participant's 12-month survey; reported at end of study year 2
Secondary Mean perceived Quality of Care score at baseline using the Patient Assessment of Chronic Illness Care survey Measured in the baseline participant survey using the Patient Assessment of Chronic Illness Care scale, a 20-item survey with 5 Likert-type responses from 1=None of the time to 5=Always. Item scores are averaged to yield an overall scale score between 1 and 5, with 1 indicating the lowest perceived care quality and 5 indicating the highest. Measured in each participant's baseline survey; reported at end of study year 1
Secondary Mean perceived Quality of Care score at 12 months using the Patient Assessment of Chronic Illness Care survey Measured in the 12-month participant survey using the Patient Assessment of Chronic Illness Care scale, a 20-item survey with 5 Likert-type responses from 1=None of the time to 5=Always. Item scores are averaged to yield an overall scale score between 1 and 5, with 1 indicating the lowest perceived care quality and 5 indicating the highest. Measured in each participant's 12-month survey; reported at end of study year 2
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Active, not recruiting NCT04989907 - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Active, not recruiting NCT04990258 - A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Completed NCT06216223 - Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients N/A
Enrolling by invitation NCT06015789 - Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
Recruiting NCT06065995 - StoMakker Mobile Application N/A
Recruiting NCT03282786 - Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease N/A
Recruiting NCT06002074 - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases N/A
Recruiting NCT04960826 - Study of an Environmental Risk Factor in Crohn's Disease
Recruiting NCT05413941 - Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease N/A
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT00721812 - A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 Phase 1
Recruiting NCT05809999 - IBD Neoplasia Surveillance RCT N/A
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Recruiting NCT04991324 - Cholecalciferol Comedication in IBD - the 5C-study Phase 3
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Not yet recruiting NCT05043818 - A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A